Early immunotherapy is highly effective in IgG1/IgG4 positive IgLON5 disease

Detalles Bibliográficos
Autores principales: Grüter, Thomas, Behrendt, Volker, Bien, Corinna I., Gold, Ralf, Ayzenberg, Ilya
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2020
Materias:
Letter to the Editors
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7320942/
https://www.ncbi.nlm.nih.gov/pubmed/32444985
http://dx.doi.org/10.1007/s00415-020-09924-y
_version_ 1783551350277144576
author Grüter, Thomas
Behrendt, Volker
Bien, Corinna I.
Gold, Ralf
Ayzenberg, Ilya
author_facet Grüter, Thomas
Behrendt, Volker
Bien, Corinna I.
Gold, Ralf
Ayzenberg, Ilya
author_sort Grüter, Thomas
collection PubMed
description
format Online
Article
Text
id pubmed-7320942
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-73209422020-07-01 Early immunotherapy is highly effective in IgG1/IgG4 positive IgLON5 disease Grüter, Thomas Behrendt, Volker Bien, Corinna I. Gold, Ralf Ayzenberg, Ilya J Neurol Letter to the Editors Springer Berlin Heidelberg 2020-05-22 2020 /pmc/articles/PMC7320942/ /pubmed/32444985 http://dx.doi.org/10.1007/s00415-020-09924-y Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
spellingShingle Letter to the Editors
Grüter, Thomas
Behrendt, Volker
Bien, Corinna I.
Gold, Ralf
Ayzenberg, Ilya
Early immunotherapy is highly effective in IgG1/IgG4 positive IgLON5 disease
title Early immunotherapy is highly effective in IgG1/IgG4 positive IgLON5 disease
title_full Early immunotherapy is highly effective in IgG1/IgG4 positive IgLON5 disease
title_fullStr Early immunotherapy is highly effective in IgG1/IgG4 positive IgLON5 disease
title_full_unstemmed Early immunotherapy is highly effective in IgG1/IgG4 positive IgLON5 disease
title_short Early immunotherapy is highly effective in IgG1/IgG4 positive IgLON5 disease
title_sort early immunotherapy is highly effective in igg1/igg4 positive iglon5 disease
topic Letter to the Editors
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7320942/
https://www.ncbi.nlm.nih.gov/pubmed/32444985
http://dx.doi.org/10.1007/s00415-020-09924-y
work_keys_str_mv AT gruterthomas earlyimmunotherapyishighlyeffectiveinigg1igg4positiveiglon5disease
AT behrendtvolker earlyimmunotherapyishighlyeffectiveinigg1igg4positiveiglon5disease
AT biencorinnai earlyimmunotherapyishighlyeffectiveinigg1igg4positiveiglon5disease
AT goldralf earlyimmunotherapyishighlyeffectiveinigg1igg4positiveiglon5disease
AT ayzenbergilya earlyimmunotherapyishighlyeffectiveinigg1igg4positiveiglon5disease

Ejemplares similares